Prescribing
Information
DARZALEX
FASPRO
®
DARZALEX
®
This site is intended for US healthcare professionals.
Prescribing Information
DARZALEX
FASPRO
®
DARZALEX
®
Get in Touch
Dosing & Administration Guide
DARZALEX
FASPRO
®
DARZALEX
®
Support & Resources
Expert Videos
MOA
Additional Regimens
NCCN Guidelines
Practice Support
Patient Support & Resources
Get in
Touch
FAQ
s
Patient Site
MM Portfolio
For APPs & Nurses
For APPs
& Nurses
Explore a DRd
Regimen
Discover a DVRd
Regimen
Continuous
Treatment
CHOOSE REGIMEN
Explore a DRd
Regimen
Explore a DRd Regimen
Discover a DVRd Regimen
Continuous Treatment
MAIA: DRd in
Transplant-Ineligible
NDMM
MAIA Study
Design
Proven Efficacy
Demonstrated
Safety Profile
Dosing
Exploratory
Subgroup
Analyses
High-Risk
Subgroup
Frailty
Subgroup
Age
Subgroup
Prescribing
Information
DARZALEX
FASPRO
®
DARZALEX
®
This site is intended for US healthcare professionals.
Prescribing Information
DARZALEX
FASPRO
®
DARZALEX
®
Get in Touch
Dosing & Administration Guide
DARZALEX
FASPRO
®
DARZALEX
®
Support & Resources
Expert Videos
MOA
Additional Regimens
NCCN Guidelines
Practice Support
Patient Support & Resources
Get in
Touch
FAQ
s
Patient Site
MM Portfolio
For APPs & Nurses
DARZALEX
FASPRO
®
monotherapy is the first and only FDA-approved treatment in
high-risk smoldering multiple myeloma
1
DARZALEX
FASPRO
®
monotherapy is now approved in
high-risk smoldering multiple myeloma
1
Cookie Policy
Loading HTML...
NEXT
Return Home
